Jump to main content
Jump to site search


Discovery of human lactate dehydrogenase A (LDHA) inhibitors as anticancer agents to inhibit the proliferation of MG-63 osteosarcoma cells

Abstract

Human lactate dehydrogenase A (LDHA) has been identified as a potential therapeutic target in the area of cancer metabolism. Herein, we report the discovery of novel LDHA inhibitors through docking-based virtual screening and biological assays. The primary enzymatic assay suggested that compound 11 targeted to LDHA with an IC50 value of 0.33 µM. The in vitro cytotoxic assay demonstrated that compound 11 reduced the growth of MG-63 cancer cells with an EC50 value of 3.35 µM. Finally, we found that compound 11 induced apoptosis of MG-63 cancer cells in a dose dependent manner, upregulated the oxygen consumption rate (OCR), decreased the lactate formation and extracellular acidification rate (ECAR) in MG-63 cancer cells. Collectively, our data suggested that compound 11 could be a promising lead for the development of potent LDHA inhibitor.

Back to tab navigation

Publication details

The article was received on 02 May 2017, accepted on 06 Jul 2017 and first published on 07 Jul 2017


Article type: Research Article
DOI: 10.1039/C7MD00222J
Citation: Med. Chem. Commun., 2017, Accepted Manuscript
  •   Request permissions

    Discovery of human lactate dehydrogenase A (LDHA) inhibitors as anticancer agents to inhibit the proliferation of MG-63 osteosarcoma cells

    A. Fang, Q. Zhang, H. Fan, Y. Zhou, Y. Yao, Y. Zhang and X. Huang, Med. Chem. Commun., 2017, Accepted Manuscript , DOI: 10.1039/C7MD00222J

Search articles by author

Spotlight

Advertisements